Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment

Immune checkpoint inhibitor-induced bullous pemphigoid (ICI-BP) is a clinically debilitating immune-related adverse event in need of novel therapeutic approaches, as conventional treatment can counteract intended tumour immunity. Here we demonstrate that interleukin (IL)-4 and IL-13 expression is el...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	British journal of dermatology (1951) 2023-08, Vol.189 (3), p.339-341
Hauptverfasser:	Shipman, William D, Singh, Katelyn, Cohen, Jeffrey M, Leventhal, Jonathan, Damsky, William, Tomayko, Mary M
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - adverse effects Humans Immune Checkpoint Inhibitors - therapeutic use Interleukin-13 Pemphigoid, Bullous - chemically induced Pemphigoid, Bullous - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!